Document is current
Any future updates will be listed below
-
Authors
Shih, David J. H. https://orcid.org/0000-0002-9802-4937
Nayyar, Naema https://orcid.org/0000-0003-3436-8404
Bihun, Ivanna
Dagogo-Jack, Ibiayi
Gill, Corey M. https://orcid.org/0000-0003-4494-1948
Aquilanti, Elisa
Bertalan, Mia
Kaplan, Alexander
D’Andrea, Megan R. https://orcid.org/0000-0002-7371-4739
Chukwueke, Ugonma
Ippen, Franziska Maria
Alvarez-Breckenridge, Christopher
Camarda, Nicholas D. https://orcid.org/0000-0002-1853-0056
Lastrapes, Matthew
McCabe, Devin https://orcid.org/0000-0002-2183-4368
Kuter, Ben
Kaufman, Benjamin
Strickland, Matthew R.
Martinez-Gutierrez, Juan Carlos
Nagabhushan, Deepika
De Sauvage, Magali https://orcid.org/0000-0001-9486-945X
White, Michael D.
Castro, Brandyn A.
Hoang, Kaitlin
Kaneb, Andrew
Batchelor, Emily D.
Paek, Sun Ha https://orcid.org/0000-0003-3007-8653
Park, Sun Hye
Martinez-Lage, Maria
Berghoff, Anna S.
Merrill, Parker https://orcid.org/0000-0001-5025-7152
Gerstner, Elizabeth R.
Batchelor, Tracy T.
Frosch, Matthew P.
Frazier, Ryan P.
Borger, Darrell R.
Iafrate, A. John
Johnson, Bruce E.
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Preusser, Matthias https://orcid.org/0000-0003-3541-2315
Cahill, Daniel P.
Carter, Scott L. https://orcid.org/0000-0002-8480-1475
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA227156-01, 1R01CA227156-01)
Brain Science Foundation
Damon Runyon Cancer Research Foundation
American Brain Tumor Association
Breast Cancer Research Foundation
Gouvernement du Canada | Canadian Institutes of Health Research
- License Information
-
More Information
Article History
Received: 19 January 2019
Accepted: 18 February 2020
First Online: 23 March 2020
Competing interests
: I.D.-J. has received honoraria from Foundation Medicine, consulting fees from Boehringer Ingelheim, travel support from Pfizer and Array, and research support from Pfizer, Genentech, Array and Novartis. A.S.B. has research support from Daiichi Sankyo (≤10,000€), Roche (>10,000€) and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo (all <5,000€) as well as travel support from Roche, Amgen and AbbVie. B.E.J. has received postmarketing royalties from the Dana-Farber Cancer Institute for <i>EGFR</i> mutation testing, has ownership interest (including patents) in the KEW Group and is a consultant/advisory board member for the same. T.T.B. reports receiving a commercial research grant from Pfizer, has received speakers’ bureau honoraria from Research To Practice, Imedex and Oakstone, and is a consultant/advisory board member for Proximagen, Merck, Foundation Medicine, UpToDate and Champions Biotechnology. S.S. consults for RareCyte. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer; Bristol-Myers Squibb; Novartis; Gerson Lehrman Group; CMC Contrast; GlaxoSmithKline; Mundipharma; Roche; BMJ Journals; MedMedia; Astra Zeneca; AbbVie; Eli Lilly and Company; MEDahead; Daiichi Sankyo; Sanofi; Merck Sharp & Dohme and Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by M.P. with payments made to his institution: Böhringer-Ingelheim; Bristol-Myers Squibb; Roche; Daiichi Sankyo; Merck Sharp & Dohme; Novocure; GlaxoSmithKline; and AbbVie. P.K.B. has consulted for Eli Lilly and Company, Tesaro, ElevateBio, Genentech-Roche and AngioChem, has received honoraria from Merck and Genentech and research funding (to Massachusetts General Hospital) from Merck, Pfizer, Eli Lilly and Company and BMS. No potential competing interests were disclosed by the other authors.
